Corcept Shares Slide After Federal Circuit Rules Against Patent Infringement
Shares of Corcept Therapeutics plunged after the United States Court of Appeals for the Federal Circuit concluded that Teva Pharmaceuticals did not infringe Corcept’s U.S. patents related to methods for safely administering Korlym with potent CYP3A4 inhibitors. The decision undermines patent protection that helped preserve Korlym’s market exclusivi…